Plus   Neg

Air France-KLM Feb. Total Group Traffic Up 5.6% - Quick Facts

Air France-KLM (AFRAF.PK) reported that for total group (Air France, KLM, HOP! and Transavia) traffic measured in revenue pax-kilometers increased 5.6% year-over-year for the month of February to 19.62 billion. Capacity, measured in available seat-kilometers, was 22.60 billion, up 3.6%. Load factor was 86.8%, an increase of 1.6 percentage points. For total group, number of passengers were 6.8 million, up 4.4% from a year ago.

For total passenger network (Air France, KLM, HOP!), traffic measured in revenue pax-kilometers rose 5.0% year-over-year to 18.18 billion. Capacity, measured in Available seat-kilometers, increased 3.3% to 21.03 billion. Load factor was 86.4%, up 1.4 percentage points. Number of passengers were 5.9 million, up 4.1% from previous year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT